These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25520649)

  • 21. Evaluation of Texture Analysis Parameter for Response Prediction in Patients with Hepatocellular Carcinoma Undergoing Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) Using Biphasic Contrast-enhanced CT Image Data: Correlation with Liver Perfusion CT.
    Kloth C; Thaiss WM; Kärgel R; Grimmer R; Fritz J; Ioanoviciu SD; Ketelsen D; Nikolaou K; Horger M
    Acad Radiol; 2017 Nov; 24(11):1352-1363. PubMed ID: 28652049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Immediate Post-Procedural Cone-Beam Computed Tomography (CBCT) in Predicting the Early Radiologic Response of Hepatocellular Carcinoma (HCC) Nodules to Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE).
    Fronda M; Mistretta F; Calandri M; Ciferri F; Nardelli F; Bergamasco L; Fonio P; Doriguzzi Breatta A
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
    Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
    Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the efficacy and safety of conventional transarterial chemoembolization with and without drug-eluting beads embolization for the treatment of unresectable large hepatocellular carcinoma.
    Chen S; Yu W; Zhang K; Liu W; Chen C
    Hepatol Res; 2021 Apr; 51(4):482-489. PubMed ID: 33462925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug-eluting bead transarterial chemoembolization is efficient and well-tolerated in treating elderly Chinese hepatocellular carcinoma patients.
    Zhou Y
    Int J Clin Exp Pathol; 2018; 11(10):4867-4878. PubMed ID: 31949562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased Arterio-Portal Shunt Formation after Drug-Eluting Beads TACE for Hepatocellular Carcinoma.
    Shimose S; Iwamoto H; Tanaka M; Niizeki T; Shirono T; Nakano M; Okamura S; Noda Y; Kamachi N; Sakai M; Suzuki H; Nomiyama M; Kuromatsu R; Koga H; Torimura T
    Oncology; 2020; 98(8):558-565. PubMed ID: 32422633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
    Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
    Zhang ZS; Li HZ; Ma C; Xiao YD
    BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
    Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcatheter Arterial Chemoembolization with Drug-Eluting Beads for the Treatment of Hepatocellular Carcinoma: Recommended Selection for Small-Caliber (<100 μm) Beads.
    Chang WC; Hsu HH; Chiu SH; Huang WY; Lo CH; Lin HH; Huang PC; Shih YL; Wan YL
    J Hepatocell Carcinoma; 2021; 8():937-949. PubMed ID: 34422707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computed tomography perfusion imaging for monitoring transarterial chemoembolization of hepatocellular carcinoma.
    Marquez HP; Karalli A; Haubenreisser H; Mathew RP; Alkadhi H; Brismar TB; Henzler T; Fischer MA
    Eur J Radiol; 2017 Jun; 91():160-167. PubMed ID: 28629564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transcatheter embolization of hepatocellular carcinoma with epirubicin-loaded DC beads in Chinese patients.
    Zhou GH; Sun JH; Zhang YL; Zhou TY; Nie CH; Zhu TY; Ai J; Chen SQ; Wang BQ; Yu ZN; Wang HL; Wu LM; Chen LM; Zheng SS
    Transl Cancer Res; 2019 Feb; 8(1):279-289. PubMed ID: 35116757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does Drug-Eluting Bead TACE Enhance the Local Effect of IRE? Imaging and Histopathological Evaluation in a Porcine Model.
    Isfort P; Rauen P; Na HS; Ito N; von Stillfried S; Kuhl C; Bruners P
    Cardiovasc Intervent Radiol; 2019 Jun; 42(6):880-885. PubMed ID: 30737544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Contrast-enhanced ultrasonography of hepatocellular carcinoma after chemoembolisation using drug-eluting beads: a pilot study focused on sustained tumor necrosis.
    Moschouris H; Malagari K; Papadaki MG; Kornezos I; Matsaidonis D
    Cardiovasc Intervent Radiol; 2010 Oct; 33(5):1022-7. PubMed ID: 20101403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor Enhancement and Heterogeneity Are Associated With Treatment Response to Drug-Eluting Bead Chemoembolization for Hepatocellular Carcinoma.
    Reis SP; Sutphin PD; Singal AG; Grzybowski R; Fisher S; Ball C; Xi Y; Grewal S; Kalva SP
    J Comput Assist Tomogr; 2017; 41(2):289-293. PubMed ID: 27824665
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification of perfusion reduction by using 2D-perfusion angiography following transarterial chemoembolization with drug-eluting beads.
    Maschke SK; Werncke T; Klöckner R; Rodt T; Renne J; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
    Abdom Radiol (NY); 2018 May; 43(5):1245-1253. PubMed ID: 28840307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transarterial chemoembolization using 40 µm drug eluting beads for hepatocellular carcinoma.
    Greco G; Cascella T; Facciorusso A; Nani R; Lanocita R; Morosi C; Vaiani M; Calareso G; Greco FG; Ragnanese A; Bongini MA; Marchianò AV; Mazzaferro V; Spreafico C
    World J Radiol; 2017 May; 9(5):245-252. PubMed ID: 28634515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.